BioCentury
ARTICLE | Company News

Amgen says ICER underestimates migraine patient burden

May 3, 2018 10:22 PM UTC

Amgen Inc. (NASDAQ:AMGN) said that the Institute for Clinical and Economic Review's cost-effectiveness analysis of calcitonin gene-related peptide (CGRP) inhibitors for migraine prevention underestimates patients' healthcare cost footprint.

ICER's draft evidence report, published April 11, estimated the incremental cost-effectiveness ratios for CGRP inhibitors Aimovig erenumab from Amgen and fremanezumab (TEV-48125) from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) in patients who have failed previous preventive therapies. As both therapies are under FDA review and do not yet have listed wholesale acquisition costs (WACs), ICER used a placeholder annual WAC of $8,500 in its calculations for each...